Prof. Joan-Lluis Vives Corrons is haematologist and Emeritus Professor of the University of Barcelona (Catalonia). He is currently the leader of the Erythropathology and Haematopoietic Disorders Unit at the Institute for Leukaemia Research Josep Carreras (IJC) of Badalona (Barcelona). During more than 30 years, Prof. Vives Corrons has developed his professional activity as the head of Haematology Department at the Hospital Clinic of Barcelona with experience in clinical haematology diagnosis, laboratory management, coordination of External Quality Assessment Schemes (EQAS) for haematology in Spain, physiopathology ,epidemiology and genetic mechanisms , of hereditary haemolytic anaemias (HHA) due red blood cell (RBC) and erythropoietic defects. His research interest include HHA due to RBC enzymopathies , haemoglobinopathies, and membranopathies and bone marrow erythropoietic failure due to congenital dyserythropoietic anaemias (CDA) and myelodysplastic syndromes (MDS). Since 2002 Prof Vives Corrons is the coordinator of the European Reference Network for Rare and Congenital Anaemias (ENERCA) and after his retirement, in 2017, he has become, as ENERCA coordinator, a member of the European Reference Network (ERN) for Rare Haematological Diseases (EuroBloodNet) Independent Advisory Board.
Aurelian Udristioiu, M.D,Primary Physician, EuSpLM,City Targu Jiu, Romania National Academy of Biochemical Chemistry (NACB) Member, Washington D.C, USA. Fellow PhD in Molecular Biology, Titu Maiorescu University, General Medicine Faculty, Bucharest, Romania. Man of Medical Year/2015 at the International Bibliographic Center, IBC, Cambridge, UK.His current research project is "The correlation between the cellular energy expressed in ATP and levels of mutant p53 protein in CLL.He is member of Cancer Epigenetics Society and member of American Society of Clinical Laboratory(ASCLS), Bethesda, USA.He has received many National and International awards.
Dr. Patrick B. Johnston, Associate Professor of Medicine and consultant in Hematology, Blood and Marrow Transplant and Immune Effector Cell Therapy, Mayo Clinic, Rochester, Minnesota, USA, grew up in the United States. He received his bachelor's degree Summa Cum Laude in physics from Mississippi State University in 1987. He received his PhD in microbiology from the University of Alabama at Birmingham in 1995. His studies were focused on retroviral envelope protein trafficking. He received his MD from the University Of Alabama School Of Medicine in 1995. He completed his internal medicine residency at the Mayo Graduate School of Medicine in 1998. He subsequently completed a Heme-Onc fellowship at the same institution in 2001. He was awarded a Mayo foundation scholarship for advanced studies and investigated anti-sence RNA inhibition in anaplastic large cell lymphoma at the University of Southern California. He returned to Mayo Clinic in 2003 and has pursued translational medicine in the treatment of lymphoma to present. His research is focused on incorporation of novel agents alone, or in combination with chemotherapy as treatment modalities. He is served as the primary investigator on greater than 20 clinical trials, including NCI sponsored cooperative group trials and investigator initiated trials.
Prof. Ruggiero received his medical degree from the Catholic University in Rome in 1992. He holds Board of Pediatrics in 1996 and Board of Pediatric Haematology and Oncology in 1998 at the Catholic University of Rome. Prof. Ruggiero is currently an associate professor in the Department of Pediatrics at the Catholic University of Rome where he is responsible for teaching Pediatrics and Pediatric Hematology and Oncology. At present he is chief of the Pediatric Oncology Unit of the Gemelli Hospital- Catholic University of Rome. Carrying a regular patient load as consultant in pediatric hemato-oncology allows him to maintain his clinical skillsand to promote improvements in safety and quality of healthcare. Examples of activities include producing guidelines for prevention of healthcare associated treatments and improvements in basic safe medical practices. His research interests focus on pediatric clinical trials, clinical pharmacology of antineoplastic drugs, pain therapy and pediatric drugs.
Dr. Carmelo Cuffari is a pediatric gastroenterologist and clinical researcher at The Johns Hopkins University, Associate Professor of Pediatrics, and Director of the Pediatric GI Fellowship Program. He received his medical degree from University of Ottawa Faculty of Medicine and has been in practice for more than 20 years. My primary interest is on understanding the pharmacogenomics and pharmaco-kinetics of drug metabolism in children and adolescents with a number of gastrointestinal disorders, including Inflammatory Bowel Disease.His work has been primarily focused at applyingthese pharmacological principles into pediatric practice with the aim of improving overall clinical response to drug therapy while minimizing the risk of drug toxicity.He has been involved in many clinical research studies involving a number of immunosuppressant drug therapies, including azathioprine, purinethol and mycophenolatemofetil. This work has led to the application of drug monitoring and the provision of these services into clinical practice within the Advanced Clinical Practice Diagnostic laboratory (ACPDL) at The Johns Hopkins Hospital. In collaboration with the ACPDL, Quality control studies are presently aimed at insuring the reproducibility of our drug monitoring services, and in providing a comparative analysis with what is available commercially. At present, his focus is in applying these same principles into the development of drug therapies in children with gastrointestinal disorders.He is the Principle National Investigator on a number of clinical trials that have been designed specifically to study the pharmacodynamics of novel formulations of mesalamine in children with ulcerative colitis, and a novel “potentiator” of the CFTR receptor therapy in children with cystic fibrosis.All of these studies are focused on providing a tailored pediatric perspective to drug dosing in children with ulcerative colitis and cystic fibrosis, respectively.He has authored greater than 100 papers, chapters and invited reviews, most of which address clinical outcomes and quality of life for children with pediatric gastrointestinal disease.He is serving as Fellowship Director at The Johns Hopkins, and takes great pride in mentoring trainees in patient care and in research.He has been directly involved in mentoring 15 research fellows of whom 90% currently have academic appointments and continue to be actively involved in academics. He has been Fellow of The Royal College of Physicians and Surgeons (FRCP) of Canada; The American Gastroenterological Association;The American College of Gastroenterology etc.
Prof. Ehud Razin received his B.Sc.in Biology and M.Sc. in Microbiology from the Hebrew University and his Ph.D. in Immunology from the Weizmann Institute of Science, Rehovot, Israel. He has for many years been a major contributor and leading scientist in the field of mast cell biology. His long term goal has been to try to ascertain the regulation of gene transcription in mast cells due to their interaction with their growth factors and in response to trigger by immunological stimulus through their surface FCεRI receptors. His team observed that in variety of cells LysRS forms a complex with either MITF or USF2, while Ap4A produced by pS-LysRS causes the release of Hint-1 from these two transcription factors. Diadenosine tetraphosphate (Ap4A) is a small molecule composed of two adenosine moieties joined in a 5′-5′ linkage by a chain of four phosphates. It is found in all living cells both in prokaryotes and in eukaryotes and his team identified it as a bona fide second messenger. It is synthesized by LysRS mainly in physiologically activated eukaryotic cells after phosphorylation of LysRS on serine 207. The LysRS–Ap4A signaling pathway was discovered and characterized by his team in cell culture systems (http://www.youtube.com/watch?v=NGgMEz79NX4). This pioneering research on the role of this signaling pathway has broken new ground in understanding its role in variety of tissues under pathological conditions.His team found that both MITF and USF2 transcription factors are positively regulated by Ap4A synthesiszed by phosphorylated LysRS allowing the transcription of their respective target genes.
Daniela de Oliveira Werneck Rodrigues, MD PhMedicine, Graduated in Medicine from the Federal University of Juiz de Fora (UFJF), has a master's degree in Health Sciences, an area of concentration in Hematology and Hemotherapy and a Doctorate in Medicine in the area of Brazilian Health, Sickle Cell Anemia. Specialist in Hematologist and Hemotherapy at the Brazilian Association of Hematology and Hemotherapy. Responsible for the Hemoglobinopathies and Hereditary Coagulopathies Service in Fundação Hemominas Juiz de Fora. Adjunct professor of hematology and hemotherapy in the medical course. Member of the Global Sickle Cell Disease Network. Researcher and coordinator of the international longitudinal multicenter study REDS III/ IV, in transfusion safety in sickle cell disease. REDS-IV-P builds on REDS-III with an additional focus on research with newborns, children, and pregnant women who need transfusions. The data compiled in REDS-IV-P will allow investigators to rapidly address key research questions in transfusion medicine and inform blood policy decisions, for adults as well as for children and other understudied patient populations.REDS-IV-P also extends the Brazilian sickle cell disease cohort that was established in REDS-III to evaluate transfusion practices and associated clinical outcomes in sickle cell disease.
Dr. Mariano Martin-Loeches worked as Medical Director in the Human Reproduction Unit of the Hospital San Carlos de Denia in Alicante. Also, worked as faculty of the Postgraduate Course in Biology of Human Reproduction by the Faculty of Medicine of the University of Alicante. He did his training in the specialty of Obstetrics and Gynecology entirely in the Department of Obstetrics and Gynecology at the University Hospital. He developed his degree at the Faculty of Medicine and Dentistry belonging to the La Nau, from October 1981 to September 1988. Dr. Mariano Martin-Loeches holds his PhD courses in the Department of Pediatrics, Obstetrics and Gynecology. He is a Member of the Executive Committee of the area 12 in the phase of Provision of Extraordinary consolidation process used for the selection and provision of places of family planning doctor in dependent on the Department of Health Institutions. He is an Editorial board member of the Journal of Obstetrics Gynecology and (AGM) since October 12, 2015. He is a Founding member of the Society of Obstetrics and Gynecology of Valencia. Also Full member of the Spanish Fertility Society. He was awarded the European University Diploma of Endoscopia Operaroria in Gynecology, in the 5th edition of the course held in April 1999 at the University Hospital in Alcalá de Henares (Madrid).
VassilisKatsares is a Biologist with a PhD in Populational Molecular Genetics from Aristotle University, Thessaloniki, Greece. He completed three Postdoctoral Fellowships covering many aspects of Molecular Genetics. He also served as a lecturer for undergraduate and postgraduate courses. He had worked as Technical Sales Support at Siemens Healthcare Diagnostics and afterwards he was the Laboratory Director at a biopharmaceutical company. Furthermore, he had been the Microbiology Lab Director at Embryolab IVF Unit for 6 years and since 2017 he is the Quality Assurance Manager at the Microbiology-Hematology Laboratory at St. Luke’s Hospital, Thessaloniki, Greece. His main research interests cover many aspects of Microbiology, Hematology, Molecular Diagnostics, Cellular Therapy projects, and bioethics. He has authored 21 scientific papers and 37 announcements at national and international conferences. He is a referee in various journals. He is member in many international Scientific Organizations and Societies. His CV is included in “Who is Who in the World”, and in “Who is Who in Science and Engineering”.
(MAJ Dr. Sorush Niknamian PhD CRFM PE APA_FPD AICP MWSES MLPI MACRO MTMA MRSB FIMS FChE EMBS FNNECOS FTSCO ANCC, AANP, ACPE, ACHE, ADA CERP APA FMDCSCO FSASS) Ph.D. in Cell and Molecular Biology and Oncology and Professor of Cell and Molecular Biology, Oncology and Biological Attacks. He is a Professional Biologist, Senior Research Scientist, Chartered Scientist and Registered His Science Council ID is: A-0008833. He is one of United Kingdom and Indiana Cancer Consortium (ICC) certified. He is a Registered Researcher in the U.S. Government's System for Award Management, Registered Scientist at National Center for Biotechnology Information. He is studying Medicine/Military Medicine at Liberty University (LU), Lynchburg, VA, United States of America. He holds Bachelor’s Degree in Mechatronics Engineering, applied Mathematics, Civil Engineering and Management. He is a Member of US Government National Science Foundation, Member of Hera Swiss Volunteers (ID: 198036), Member of US Army American College of Physicians Chapter, Ambassador of American Cancer Society (ACS CAN) and former Ambassador of European Association for Cancer Research (EACR), Active Member of Federal Health Professionals at US Army Forces and Certified Member of American Red Cross and Food Regulatory Affairs Professionals. He is an Honorary Board Member and contributor of Weston A Price Foundation (WAPF) in Washington DC, United States of America. He Holds Honorary Doctorate of Cancer Biology and Doctor of Science from Violet Cancer Institute. He is preserved and nominated for the preserved as Position Title: DIRECTOR OF MILITARY SUPPORT, Agency: Army National Guard Units. Announcement Number: ID: WA-10507254-AR-19-161. Extra Information: DIRECTOR OF MILITARY SUPPORT located at the WASHINGTON J3 DCSOPS. Professor Sorush Niknamian is an ACP Chapter member in United States Army and Air Force. Active Member of IMRTC-USA (International Management Research and Technology Consortium Research) as Advisor, Referee and Professor at IMRTC-USA (International Management Research and Technology Consortium Panel). He is a Service Member of Modern Military Association of America. Certified Member of World Medical Association with ID: 5c7b154b01602 as a Junior Medical Doctor. He is an Active Member of the National Guard Association of the United States of America (Branch: Army, Rank: Major, State Affiliation: Maryland) and Serving Volunteer at the Peace Corps of the United States of America (Ref ID: 10811430) and certified member of The National Bureau of Asian Research. He is a member of Military Officers Association of America (Member Number: 05670401, Rank: Major). He is one of the certified member of Texas Section of the American Physical Society. Active Member of the United Nation (ROSTER NUMBER – 1665156). MAJ Dr. Sorush Niknamian is a Certified and professional in Terrorism Affairs, Terrorism Analysis and Terrorism Counterterrorism from American Military University (AMU). He has been written more than 30 books in different area of science specially Medicine, Evolutionary Biology, Nutrition and Oncology. He has published more than 120 research articles in International and National scientific journals. He is an activist in ASCO Action Network in Virginia. He is an active Member of Physicians for human rights. He is an active member of Federal Planners' Advocacy Network.